Unión Europea -
noruego -
EMA (European Medicines Agency)
protopic
leo pharma a/s - takrolimus - dermatitt, atopisk - andre dermatologiske preparater - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. forekommer fire ganger eller mer per år) som har hatt et første svar til maksimalt seks uker behandling av to ganger daglig takrolimus salve (lesjoner ryddet, nesten ryddet eller mildt rammet).
Noruega -
noruego -
Statens legemiddelverk
frontline 100 mg/ ml
orifarm as - fipronil til dyr - påflekkingsvæske, oppløsning - 100 mg/ ml
Noruega -
noruego -
Statens legemiddelverk
frontline 100 mg/ ml
orifarm as - fipronil til dyr - påflekkingsvæske, oppløsning - 100 mg/ ml
Noruega -
noruego -
Statens legemiddelverk
frontline 100 mg/ ml
orifarm as - fipronil til dyr - påflekkingsvæske, oppløsning - 100 mg/ ml
Unión Europea -
noruego -
EMA (European Medicines Agency)
adtralza
leo pharma a/s - tralokinumab - dermatitt, atopisk - andre dermatologiske preparater - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
Unión Europea -
noruego -
EMA (European Medicines Agency)
evrysdi
roche registration gmbh - risdiplam - muskelatrofi, spinal - andre legemidler for forstyrrelser i muskel-skjelettsystemet - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
Noruega -
noruego -
Statens legemiddelverk
daivobet 50 mikrog/ g / 0.5 mg/ g
orifarm as - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g